[
    "-amine<img id=\"EMI-C00023\" path=\"US10188642-20190129-C00023.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096062/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00023.TIF\"/>\nMethod A\n</p>A suspension of 3-chloro-6-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-4-yl)-isoquinoline (Preparation 1, 10.5 mg, 0.03 mmol), 4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyaniline (Preparation 74, 8.4 mg, 0.04 mmol), xantphos (11.2 mg, 0.02 mmol), Pd<sub>2</sub>(dba)<sub>3 </sub>(2.9 mg, 0.003 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(83 mg, 0.26 mmol) in toluene/DMF (3/1 mL) was stirred at 160\u00b0 C. under microwave irradiation for 2 hours. The reaction mixture was filtered, diluted with NaCl solution and extracted with EtOAc. The organic layer was purified by SCX-2 column eluting with 2M NH<sub>3</sub>/MeOH and concentrated in vacuo. The residue was purified using Biotage silica gel column chromatography eluting with 0-12% MeOH in EtOAc to afford the title compound (4.5 mg, 28%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 8.96 (d, J=1.1 Hz, 1H), 7.98-7.93 (m, 2H), 7.85 (d, J=8.4 Hz, 1H), 7.77 (t, J=1.0 Hz, 1H), 7.71 (d, J=1.5 Hz, 1H), 7.48 (dt, J=8.5, 1.5 Hz, 1H), 7.27 (s, 1H), 7.18 (s, 1H), 7.03-6.96 (m, 2H), 6.92 (d, J=1.9 Hz, 1H), 4.08 (d, J=8.0 Hz, 2H), 4.06-3.99 (m, 2H), 3.97 (s, 3H), 3.59 (s, 3H), 3.41 (td, J=11.8, 2.1 Hz, 2H), 2.52 (s, 3H), 2.30-2.20 (m, 1H), 1.62-1.53 (m, 2H), 1.50-1.38 (m, 2H).</p>LCMS (ESI) Rt=1.92 minutes MS m/z 509 [M+H]<sup>+</sup></p>MPS1 IC50 (\u03bcM): 0.002</p>The following Examples were prepared according to Method A (Example 1) above using the appropriate chloroisoquinoline and 4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyaniline (Preparation 74) unless otherwise described. The crude reaction residues were purified as above or according to one of the following methods:</p>Method A: Biotage silica gel column chromatography eluting with between 0-6% MeOH/EtOAc</p>Method B: Biotage silica gel column chromatography eluting with 0-6% MeOH/EtOAc followed by preparative HPLC.</p>Method C: Biotage silica gel column chromatography eluting with 0-15% MeOH/EtOAc.</p>Method D: Preparative HPLC followed by, where necessary elution though an SCX-2 cartridge using 2M NH<sub>3</sub>/MeOH.</p>Method E: Biotage silica gel column chromatography eluting with 0-8% MeOH/EtOAc.</p>Method F: Biotage silica gel column chromatography eluting with 0-10% MeOH/EtOAc followed by preparative HPLC.</p>Method G: Biotage silica gel column chromatography eluting with between 50-100% EtOAc in cyclohexanes.</p>Method H: Biotage silica gel column chromatography eluting with EtOAc.</p>Method I: Elution through an SCX-2 cartridge using 50% MeOH in chloroform followed by 50% chloroform in 7N NH<sub>3</sub>/MeOH, followed by silica gel column chromatography eluting with 0-10% 7N NH<sub>3</sub>/MeOH in EtOAc.</p>Method J: Elution through an SCX-2 cartridge using 50% MeOH in chloroform followed by 50% chloroform in 7N NH<sub>3</sub>/MeOH, followed by sili",
    "sup>H NMR (500 MHz, CD<sub>3</sub>OD): \u03b4 8.99 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.6 Hz, 1H), 7.88 (dd, J = 8.6, 1.6 Hz, 1H), 7.42 (s, 1H), 7.33 (d, J = 1.9 Hz, 1H), 7.27 (dd, J = 8.4, 1.9 Hz, 1H), 4.6 (br s, 1H), 4.49 (s, 2H), 4.32-4.3 (m, 3H), 4.31-4.29 (m, 2H), 4.1-3.99 (m, 1H), 4 ( s, 3H), 3.34 (s, 3H), 1.29 (s, 6H). HRMS (ESI) MS m/z calcd for C<sub>27</sub>H<sub>31</sub>N<sub>6</sub>O<sub>4 </sub>[M + H] 503.2446 Using 1-(4-(3-chloroisoquinolin-6-yl)-2H- 1,2,3-triazol-2-yl)-2-methylpropan-2-ol (Preparation 48) and (4-amino-3- methoxyphenyl)(3-methoxyazetidin-1- yl)methanone (Preparation 92) and purification method A.0.009</p>Examples 98 and 99: (R) and (S) enantiomers of 1-(4-(3-((4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)amino)isoquinolin-6-yl)-1H-pyrazol-1-yl)propan-2-ol<img id=\"EMI-C00120\" path=\"US10188642-20190129-C00120.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096148/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00120.TIF\"/></p>The (R) and (S) enantiomers of 1-(4-(3-((4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)amino)isoquinolin-6-yl)-1H-pyrazol-1-yl)propan-2-ol (Example 38) were separated using a Chiralpak IA column (20 uM, 250\u00d710 mm), using a Gilson GX-281 liquid handler system combined with a Gilson 322 HPLC pump over a 40 minute isocratic elution at 80% MeCN/20% propan-2-ol (both modified with 0.1% diethylamine) at a flow rate of 5 mL/min.</p>Example 98Rt=10.6 minutes ee&gt;99% MPS1 IC50 (\u03bcM): 0.003</p>Example 99Rt=16.1 minutes ee&gt;99% MPS1 IC50 (\u03bcM): 0.005</p>Example 100N-(2-Methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridin-7-amine<img id=\"EMI-C00121\" path=\"US10188642-20190129-C00121.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096231/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00121.TIF\"/>\nMethod B\n</p>To 7-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridine (Preparation 58, 25 mg 0.086 mmol) and 2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline (Preparation 91, 18.4 mg 0.091 mmol) was added cesium carbonate (56 mg 0.17 mmol) and Xantphos (5.0 mg 0.0086 mmol). DMA (0.95 mL) was added and the mixture degassed with nitrogen. Palladium<sub>2</sub>(dba)<sub>3 </sub>complex (3.94 mg 0.0044 mmol) was added and the reaction heated to 80\u00b0 C. for 5 hours. The reaction was cooled and diluted with ethyl acetate (15 mL). The solution was washed with water (3\u00d75 mL), brine, dried over sodium sulphate and concentrated in vacuo. The residue was purified by preparative TLC eluting with 10% EtOH in EtOAc followed by trituration with diethyl ether to afford the title compound (18 mg, 50%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 8.87 (s, 1H), 8.15 (br s, 1H), 8.10 (s, 1H), 8.06 (d, J=8.20 Hz, 1H), 7.83 (d, J=8.20 Hz, 1H), 7.62 (d, J=0.63 Hz, 1H), 7.40 (br s, 1H), 7.40 (d, J=8.20 Hz, 1H), 7.17 (br s, 1H), 7.13 (dd, J=1.89, 8.20 Hz, 1H), 7.04 (d, J=1.89 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 3.96 (s, 3H).</p>HRMS (ESI) MS m/z calcd for C<sub>23</sub>H<sub>22</sub>N<sub>7</sub>O [M+H]<sup>+ </sup>412.1880, found 412.1880. Rt=2.51 minutes.</p>MPS1 IC50 (\u03bcM): 0.006</p>The following Examples were prepared according to Method B (Example 100) above using the appropriate halo-naphthyridine and aniline as described below. The crude reaction residues were purified as above or according to one of the following methods:</p>Method A: Trituration with EtOAc followed by diethyl ether.</p>Method B: Grade III basic alumina column chromatography eluting with a gradient of 0-10% EtOH in DCM.</p>Method C: Elution though an SCX-2 cartridge using 2M NH<sub>3</sub>/MeOH followed by preparative TLC eluting with 10% EtOH in EtOAc followed by trituration with diethylether.</p>Method D: Preparative TLC eluting with EtOAc followed by trituration with diethyl ether.</p>MPS1ExampleIC50NoName/StructureData(\u03bcM)1011-(4-(7-(2-Methoxy-4-(1- methyl-1H-pyrazol-4- yl)phenylamino)-1,6- naphthyridin-2-yl)-1H- pyrazol-1-yl)-2- methylpropan-2-ol \u2003 <img id=\"EMI-C00122\" path=\"US10188642-20190129-C00122.TIF\" file=\"https://surechembl.org/api/assets/attachment/475095627/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00122.TIF\"/>\n<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 8.87 (s, 1H), 8.23 (br s, 1H), 8.17 (s, 1H), 8.08 (d, J =  8.51 Hz, 1H), 7.83 (d, J = 8.20 Hz, 1H), 7.77 (s, 1H), 7.62 (s, 1H), 7.41 (d, J =  8.51 Hz, 1H), 7.40 (s, 1H), 7.19 (s, 1H), 7.13 (dd, J = 1.58, 7.88 Hz, 1H), 7.04 (d, J =  1.89 Hz, 1H), 4.16 (s, 2H), 3.98 (s, 3H), 3.97 (s, 3H), 1.24 (s, 6H). HRMS (ESI) MS m/z calcd for C<sub>26</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub> [M",
    " naphthyridine-2-carboxamide (Preparation 63) and 2-methoxy-4-(1- methyl-1H-pyrazol-4-yl)aniline (Preparation 91) and purification method D.0.007</p>Example 109Racemic 3-(4-(3-((4-(1,2-Dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)amino)isoquinolin-6-yl)-1H-pyrazol-1-yl)propane-1,2-diol<img id=\"EMI-C00130\" path=\"US10188642-20190129-C00130.TIF\" file=\"https://surechembl.org/api/assets/attachment/475095507/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00130.TIF\"/></p>To a solution of 6-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-4-yl)-N-(4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)isoquinolin-3-amine (Example 40, 20 mg, 0.038 mmol) in THF (8 mL) at 0\u00b0 C. was added TFA (1 mL). the reaction was stirred at room temperature for 16 hours before concentrating in vacuo. The residue was purified by elution through an SCX-2 column using 2M NH<sub>3</sub>/MeOH to afford the title compound (18 mg, 97%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 8.90 (s, 1H), 7.91-7.86 (m, 3H), 7.77 (d, J=8.50 Hz, 1H), 7.61 (d, J=1.60 Hz, 1H), 7.16-7.13 (m, 2H), 7.15 (d, J=4.48 Hz, 1H), 6.90 (dd, J=1.85, 8.20 Hz, 1H), 6.88 (s, 1H), 6.83 (d, J=1.85 Hz, 1H), 4.41-4.28 (m, 2H), 4.24-4.16 (m, 1H), 3.88 (s, 3H), 3.68 (qd, J=4.98, 11.40 Hz, 2H), 3.51 (s, 3H), 2.43 (s, 3H).</p>LCMS (ESI) Rt=1.80 minutes MS m/z 485 [M+H]<sup>+</sup></p>HRMS (ESI) MS m/z calcd for C<sub>27</sub>H<sub>29</sub>N<sub>6</sub>O<sub>3 </sub>[M+H]<sup>+ </sup>485.2296, found 485.2286. Rt=2.09 minutes.</p>MPS1 IC50 (\u03bcM): 0.003</p>Example 1101-(4-(3-((2-Methoxy-4-(2-methyl-1-(piperidin-4-ylmethyl)-1H-imidazol-5-yl)phenyl)amino)-isoquinolin-6-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol<img id=\"EMI-C00131\" path=\"US10188642-20190129-C00131.TIF\" file=\"https://surechembl.org/api/assets/attachment/475095784/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00131.TIF\"/></p>A suspension of 1-(4-(3-chloroisoquinolin-6-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol (Preparation 22, 15 mg, 0.050 mmol), tert-butyl 4-((5-(4-amino-3-methoxyphenyl)-2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate (Preparation 79, 19.9 mg, 0.050 mmol), xantphos (17.3 mg, 0.030 mmol), Pd<sub>2</sub>(dba)<sub>3 </sub>(4.6 mg, 0.005 mmol) and Cs<sub>2</sub>CO<sub>3 </sub>(130 mg, 0.398 mmol) in toluene/DMF (3/1 mL) was stirred at 160\u00b0 C. under microwave irradiation for 2 hours. The reaction mixture was filtered, diluted with NaCl solution and extracted with EtOAc. The organic solution was purified by elution through an SCX-2 column using 2M NH<sub>3</sub>/MeOH followed by preparative HPLC. The residue was dissolved in DCM (6 mL) and cooled to 0\u00b0 C. TFA (0.2 mL) was added and the reaction stirred at room temperature for 16 hours. The reaction was concentrated in vacuo and purified by elution through an SCX-2 column using 2M NH<sub>3</sub>/MeOH followed by preparative HPLC to afford the title compound as a yellow oil (2.5 mg, 59%).</p><sup>1</sup>H NMR (500 MHz, MeOD): \u03b4 8.94 (s, 1H), 8.20 (s, 1H), 8.07-8.02 (m, 2H), 7.94 (d, J=8.60 Hz, 1H), 7.90 (s, 1H), 7.65 (dd, J=1.60, 8.52 Hz, 1H), 7.36 (s, 1H), 7.10-6.99 (m, 3H), 4.19 (s, 2H), 4.14 (d, J=7.62 Hz, 2H), 4.00 (s, 3H), 3.35-3.25 (m, 2H), 2.85 (td, J=3.02, 12.88 Hz, 2H), 2.58 (s, 3H), 1.98-1.88 (m, 1H), 1.70 (d, J=13.84 Hz, 2H), 1.30-1.22 (m, 2H), 1.25 (s, 6H).</p>HRMS (ESI) MS m/z calcd for C<sub>33</sub>H<sub>40</sub>N<sub>7</sub>O<sub>2 </sub>(M+H)<sup>+</sup>566.3238, found 566.3236. Rt=2.25 minutes.</p>MPS1 IC50 (\u03bcM): 0.005</p>Example 1111-(4-(3-((2-Methoxy-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-3-yl)phenyl)amino)-isoquinolin-6-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol<img id=\"EMI-C00132\" path=\"US10188642-20190129-C00132.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096070/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00132.TIF\"/></p>The title compound was prepared according to the method described for Example 110 using 1-(1-(4-(3-chloroisoquinolin-6-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol (Preparation 22) and tert-butyl 3-(4-amino-3-methoxyphenyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate (Preparation 89).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) \u03b4 8.95 (s, 1H), 7.97 (d, J=0.78 Hz, 1H), 7.92 (d, J=8.20 Hz, 1H), 7.87-7.80 (m, 2H), 7.73-7.68 (m, 1H), 7.47 (dd, J=1.62, 8.46 Hz, 1H), 7.25 (t, J=0.94 Hz, 1H), 7.16 (s, 1H), 7.07 (s, 1H), 7.01 (dd, J=1.86, 8.16 Hz, 1H), 6.94 (d, J=1.86 Hz, 1H), 4.22 (s, 2H), 4.15 (s, 2H), 3.99 (t, J=5.40 Hz, 2H), 3.96 (s, 3H), 3.27 (t, J=5.40 Hz, 2H), 1.25 (s, 6H).</p>HRMS (ESI) MS m/z calcd for C<sub>29</sub>H<sub>32</sub>N<sub>7</sub>O<sub>2 </sub>[M+H]<sup>+ </sup>510.2612, found 510.2617. Rt=2.23 minutes.</p>MPS1 IC50 (\u03bcM): 0.003</p>Example 1121-(4-(3-(2-Methoxy-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)phenylamino)-isoquinolin-6-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol<img id=\"EMI-C00133\" path=\"US10188642-20190129-C00133.TIF\" file=\"https://surechembl.org/api/assets/attachment/475095846/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00133.TIF\"/></p>To a solution of tert-Butyl 3-(4-(6-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)isoquinolin-3-ylamino)-3-methoxyphenyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate (Example 55, 29 mg, 0.047 mmol) in DCM (10 mL) at 0\u00b0 C. was added TFA (0.35 mL). The reaction was stirred at room temperature for 16 hours before concentrating in vacuo. The residue was purified by elution through an SCX-2 column using 2M NH<sub>3</sub>/MeOH to afford the title compound as a yellow solid (17.5 mg, 72%).</p><sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>): \u03b4 8.98 (s, 1H), 8.29 (d, J=0.84 Hz, 1H), 8.27 (s, 1H), 8.17 (d, J=8.38 Hz, 1H), 8.07 (d, J=0.80 Hz, 1H), 7.94 (d, J=8.64 Hz, 1H), 7.89 (s, 1H), 7.62 (dd, J=1.64, 8.58 Hz, 1H), 7.39 (d, J=1.94 Hz, 1H), 7.34-7.28 (m, 2H), 4.24-4.06 (m, 2H+2H), 4.04 (s, 2H), 3.96 (s, 3H), 3.06 (t, J=5.46 Hz, 2H), 1.12 (s, 6H).</p>HRMS (ESI) MS m/z calcd for C<sub>28</sub>H<sub>31</sub>N<sub>8</sub>O<sub>2 </sub>[M+H]<sup>+ </sup>511.2564, found 511.2564. Rt=2.17 minutes.</p>MPS1 IC50 (\u03bcM): 0.002</p>Example 113N-(4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)isoquinolin-3-amine<img id=\"EMI-C00134\" path=\"US10188642-20190129-C00134.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096018/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00134.TIF\"/></p>To a solution of tert-butyl 4-(4-(3-((4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)-amino)isoquinolin-6-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (Example 4, 27 mg, 0.045 mmol) in DCM (6 mL) at 0\u00b0 C. was added TFA (0.6 mL) and the reaction was stirred at room temperature for 4 hours. The solvents were removed in vacuo and the residue was purified by SCX-2 column eluting with 2M NH<sub>3</sub>/MeOH to afford the title compound as a yellow oil (19 mg, 85%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 8.95 (s, 1H), 7.90-7.95 (m, 2H), 7.85-7.82 (m, 2H), 7.71 (s, 1H), 7.52-7.43 (m, 1H), 7.26 (s, 1H), 7.16 (s, 1H), 6.99 (dd, J=8.0, 2.1 Hz, 1H), 6.97 (s, 1H), 6.92 (s, 1H), 4.35-4.25 (m, 1H), 3.96 (s, 3H), 3.57 (s, 3H), 3.36-3.21 (m, 2H), 2.85-2.75 (m, 2H), 2.48 (s, 3H), 2.30-2.16 (m, 2H), 2.05-1.88 (m, 2H).</p>(Agilent ToF method) Rt=1.79 minutes MS m/z 494 [M+H]<sup>+</sup></p>MPS1 IC50 (\u03bcM): 0.004</p>Example 114N-(4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)-6-(6-(methylamino)pyridin-3-yl)isoquinolin-3-amine<img id=\"EMI-C00135\" path=\"US10188642-20190129-C00135.TIF\" file=\"https://surechembl.org/api/assets/attachment/475095587/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00135.TIF\"/></p>To a solution of tert-butyl (5-(3-((4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)-amino)isoquinolin-6-yl)pyridin-2-yl)(methyl)carbamate (Example 12, 10 mg, 0.018 mmol) in DCM (4 mL) at 0\u00b0 C. was added TFA (0.6 mL). The reaction was stirred at room temperature for 16 hours. The solvents were removed in vacuo and the residue was purified by SCX-2 column eluting with 2M NH<sub>3</sub>/MeOH to afford the title compound as a yellow oil (8 mg, 98%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 9.00 (d, J=1.1 Hz, 1H), 8.50 (dd, J=2.5, 1.0 Hz, 1H), 8.00-7.94 (m, 1H), 7.90 (d, J=8.6 Hz, 1H), 7.83 (ddd, J=8.5, 2.4, 1.7 Hz, 1H), 7.73 (d, J=1.6 Hz, 1H), 7.53 (dt, J=8.3, 1.6 Hz, 1H), 7.31 (d, J=1.5 Hz, 1H), 7.19 (s, 1H), 7.04-6.96 (m, 2H), 6.93 (d, J=1.8 Hz, 1H), 6.54 (dd, J=8.7, 0.9 Hz, 1H), 3.97 (s, 39H), 3.59 (s, 3H), 3.02 (s, 3H), 2.50 (s, 3H).</p>(Agilent ToF method) Rt=1.77 minutes MS m/z 451 [M+H]<sup>+</sup></p>MPS1 IC50 (\u03bcM): 0.021</p>Example 115N-(4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)-7-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-d]pyrimidin-2-amine<img id=\"EMI-C00136\" path=\"US10188642-20190129-C00136.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096057/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00136.TIF\"/></p>A suspension of 2-chloro-7-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-d]pyrimidine (Preparation 55, 7.5 mg, 0.03 mmol), 4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyaniline (Preparation 74, 10 mg, 0.05 mmol), R-(+)BINAP (2 mg, 3 umol), Pd(OAc)<sub>2 </sub>(0.69 mg, 3 umol), K<sub>2</sub>CO<sub>3 </sub>(42 mg, 0.31 mmol) in DMF (3 mL) was stirred at 160\u00b0 C. under microwave irradiation for 2 hours. The reaction mixture was filtered, diluted with NaCl solution and extracted with EtOAc. The organic layer was purified by SCX-2 column eluting with 2M NH<sub>3 </sub>in MeOH and concentrated in vacuo. The residue was purified by Biotage silica gel column chromatography eluting with 0-10% MeOH in EtOAc followed by preparative HPLC to afford the title compound (4 mg, 31%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 9.07 (s, 1H), 9.03-9.01 (m, 1H), 8.27 (s, 1H), 8.25 (d, J=14.0 Hz, 1H), 8.17 (d, J=0.7 Hz, 1H), 8.07 (d, J=8.3 Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 7.17-6.99 (m, 2H), 6.89 (d, J=1.8 Hz, 1H), 4.03 (s, 3H), 3.98 (s, 3H), 3.62 (s, 3H), 2.64 (s, 3H).</p>LCMS (ESI) Rt=1.87 minutes MS m/z 427 [M+H]<sup>+</sup></p>MPS1 IC50 (\u03bcM): 0.016</p>Example 1161-(4-(2-((4-(1,2-Dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol<img id=\"EMI-C00137\" path=\"US10188642-20190129-C00137.TIF\" file=\"https://surechembl.org/api/assets/attachment/475096228/US/20190129/B2/000010/18/86/42/US10188642-20190129-C00137.TIF\"/></p>A suspension of NaH (4.3 mg), 2-methyl-1-(4-(2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7-yl)-1H-pyrazol-1-yl)propan-2-ol (Preparation 69, 15.5 mg, 0.045 mmol), N-(4-(1,2-dimethyl-1H-imidazol-5-yl)-2-methoxyphenyl)formamide (Preparation 74, 16.4 mg, 0.067 mmol) in NMP/THF (\u2153 mL) was stirred at 160\u00b0 C. under microwave irradiation for 2 hours. The reaction mixture was filtered, diluted with NaCl solution and extracted with EtOAc. The EtOAc portion was purified by elution through an SCX-2 column using 2M NH<sub>3</sub>/MeOH to give the title compound as yellow oil (3 mg, 14%).</p><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): \u03b4 9.09 (s, 1H), 9.03 (s, broad, 1H), 8.36 (s, 1H), 8.27-8.20 (m, 2H), 8.09 (d, J=8.24 Hz, 1H), 7.55 (d, J=8.24 Hz, 1H), 7.11 (s, 1H), 7.08 (dd, J=1.86, 8.34 Hz, 1H), 6.91 (d, J=1.86 Hz, 1H), 4.20 (s, 2H), 3.99 (s, 3H), 3.63 (s, 3H), 2.66 (s, 3H), 1.26 (s, 6H).</p>HRMS (ESI) MS m/z calcd for C<sub>26</sub>H<sub>29</sub>N<sub>8</sub>O<sub>2 </sub>[M+H]<sup>+ </sup>485.2408, found 485.2399.</p>Preparation MethodsPreparation 1: 3-Chloro-6-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-4-yl)isoquinoline<img id=\"EMI-C00"
]